A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity
PLoS One 7(10):e0275901, 2022
GIP affects hepatic fat and brown adipose tissue thermogenesis, but not white adipose tissue transcriptome in T1D
Journal of Clinical Endocrinology and Metabolism 107(12):3261-3274, 2022
LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
Cell Reports Medicine 3(4):100582, 2022
New insights into disease progression and human translatability of the GAN DIO-NASH mouse
Join preclinical NASH experts Michael Feigh and Henrik Björk Hansen in a scientist-to-scientist talk about the latest research discoveries and advances within human translational models of non-alcoholic steatohepatitis (NASH).
Preclinical drug discovery in NASH – Narrowing the translational gap
In this webinar Principal Scientist at Gubra Henrik Björk Hansen discusses strategies to improve clinical translatability of preclinical models of NASH. The webinar introduces a diet-induced obese and biopsy-confirmed rodent model of NASH with progressive development of fibrosis and hepatocellular carcinoma, that recapitulates…
Interferon lambda 4 genotype and pathway in alcoholic hepatitis
Scandinavian Journal of Gastroenterology 56(3):304-311, 2021
Gut mucosal gene expression and metabolic changes after Roux-en-Y gastric bypass surgery
Obesity 28(11): 2163-2174, 2020
Identification and metabolic profiling of a novel human gut-derived LEAP2 fragment
Journal of Clinical Endocrinology and Metabolism 106(2):e966-e981, 2021
Low interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression
Clinical and Translational Gastroenterology 11(8):e00197
Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
BMC Gastroenterology 20:210, 2020